November 14, 2019 09:37 AM EST

Allergan enlists Exicure in search of hair loss drugs with $25M upfront, doubling down on area dear to AbbVie

Amber Tong

After AbbVie became a formidable player in medical aesthetics overnight by swallowing Allergan, the Botox maker is beefing up the pipeline with new R …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Allergan enlists Exicure in search of hair loss drugs with $25M upfront, doubling down on area dear to AbbVie

Amber Tong

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

BridgeBio shares promising results in trial of Canavan disease gene therapy

CRISPR therapy reduces swelling attacks by 81% in Intellia follow-up study

Facing lost rebates, MGM Resorts to stop covering GLP-1 weight loss shots

Exclusive: University of Toronto spinout raises $53.5M to create new obesity drugs with AI

Icon's quarterly earnings hit by biotech and pharma pullback

IDEAYA Biosciences: Targeting unmet market needs with precision oncology

Al­ler­gan en­lists Ex­i­cure in search of hair loss drugs with $25M up­front, dou­bling down on area dear to Ab­b­Vie

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Allergan enlists Exicure in search of hair loss drugs with $25M upfront, doubling down on area dear to AbbVie